FDA Wants To Work With USPTO To Stop Gaming Of Drug Patents

By Gabrielle Wanneh / September 14, 2021 at 2:24 PM
The FDA wants to work with the U.S. Patent and Trademark Office (USPTO) to combat what the government views as anticompetitive patent practices that drug companies use to block generic and biosimilar competition, acting Commissioner Janet Woodcock wrote in a Sept. 10 letter to the patent office . The agency’s concerns include so-called patent thickets, patent evergreening and product hopping. The outreach is part of HHS’ plan for lowering drug costs , which a recent presidential executive order directed the...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.